11th International Workshop on Waldenstrom's Macroglobulinemia
Attend the world’s most comprehensive hematology/oncology event on Waldenstrom’s macroglobulinemia; the 11th International Workshop on Waldenstrom’s macroglobulinemia (IWWM-11).
The 11th International Workshop for Waldenstrom's Macroglobulinemia is being held October 27th through the 30th, 2022 in Madrid, Spain. The venue chosen for this meeting is one of Madrid’s premier hotels, Westin Palace Madrid, situated in the Las Letras quarter. The hotel nestles in one of the city’s most historic areas linking the city’s most enriching museums, Prado, Reina Sofia and Thyssen-Bornemisza, vibrant parks and gardens, and epicurean eateries. Onsite registration and check-in begin at 14:00 (2:00pm) on Wednesday, October 26th, conference sessions starting on Thursday, the 27th, at 8:00am.
The Workshop’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic system, by promoting targeted research, clinical care methods, education, training, and advocacy for Waldenstrom’s macroglobulinemia.
IWWM-11 will continue to support future research by including a Junior Investigator Poster presentation event with short oral presentations. Abstract submissions for poster presentations will begin in June 2022.
Read more: 11th International Workshop on Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Dana-Farber Researchers Use Machine Learning to Understand Rare Familial Blood Cancer
Researchers at Dana-Farber have put together a data atlas that includes a range of genomic, transcriptomic, epigenetic, and clinical data from patients and healthy donors to try to understand familial WM.
Topics from the 11th IWWM Workshop in Madrid
Bing Center WM experts discuss various topics from the 11th IWWM in Madrid.
Expert Advice for Newly Diagnosed Waldenström Macroglobulinemia (WM) Patients
What should you know if you or a loved one has been diagnosed with Waldenström macroglobulinemia (WM)? Dr. Shayna Sarosiek of the Dana-Farber Cancer Institute shares key advice.
Talking with your Waldenstrom's Macroglobulinemia Patients
This document, written by Drs. Jorge Castillo and Shayna Sarosiek, provides a reference guide to assist medical professionals in discussions with WM patients. Patients can give this booklet to their PCP, oncologist, or other health care provider in order to help familiarize them with this uncommon disease.
2022 ASH Conference Report: Waldenstrom Macroglobulinemia
From the 64th ASH Annual Meeting, Jorge Castillo, MD, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, updates our Waldenström patient community on important research results presented this year, offers guidance on finding relevant clinical trials, and highlights what to look for in the coming year.
RECORDING AVAILABLE - Treatment, Trials, and Hope-For ALL Stages of Disease
RECORDING NOW AVIALABLE! Join IWMF on ZOOM for this very important topic that affects everyone with a WM diagnosis! Dr. Jorge Castillo presents - Treatments, Trials, and Hope – for ALL Stages of Disease. Dr. Castillo is a GLOBAL SPECIALIST IN Waldenstrom's Macroglobulinemia (WM) AND Clinical Director of the Bing Center Clinic (for WM) at Dana-Farber Cancer Institute.
Everything You Want to Know About BTK Inhibitors, Do's and Don'ts
With so many patients choosing BTK inhibitors for their Waldenstrom Macroglobulinemia treatment, and new WM treatments in development, it is difficult to keep up with so much new information. This is your chance to get Dr. Jorge Castillo's expert info about BTK inhibitors, long term goals and monitoring; what to do, what not to do; complications; and even some success stories.
Bing Center Researchers Awarded Over $1M in Funding From IWMF
IWMF grant funding for research projects has helped to provide an understanding of the basic biology and genetics of WM. This research in turn has played a significant role in the development of treatments and treatment guidelines in current use, as well as potential new drugs still in the pipeline. The goal of our research program is to improve quality of life for WM patients and, ultimately, discover a cure.
Diagnosis and Management of Waldenstrom’s Macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) is a rare type of cancer that begins in the white blood cells.The abnormal white blood cells produce a protein that accumulates in the blood, impairs circulation and causes complications. It continues to be a clinical challenge for treating physicians as complete remissions and prevention of relapse are few in spite of all the therapeutic tools that are currently available. Besides treatment aspects, correct diagnosis of WM often poses a challenge.
U.S. News & World Report Names Dana-Farber Brigham Cancer Center among nation's best for 2022-2023
For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report. This year, Dana-Farber Brigham Cancer Center is ranked as the best hospital for cancer care in New England and #4 in the nation.